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Abstract
Background: Henoch Schonlein purpura (HSP) is a common vasculitis of small vessels whereas
endothelin-1 (ET-1) is usually reported elevated in vasculities and systematic inflammation. The aim
of the present study was to investigate whether ET-1 levels are correlated with the clinical
presentation and the outcome of HSP.
Methods: The study sample consisted of thirty consecutive patients with HSP. An equal number
of healthy patients of similar age and the same gender were served as controls. The patients' age
range was 2–12.6 years with a mean ± SD = 6.3 ± 3 years. All patients had a physical examination
with a renal, and an overall clinical score. Blood and urinary biochemistry, immunology
investigation, a skin biopsy and ET-1 measurements in blood and urine samples were made at
presentation, 1 month later and 1 year after the appearance of HSP. The controls underwent the
same investigation with the exception of skin biopsy.
Results: ET-1 levels in plasma and urine did not differ between patients and controls at three
distinct time points. Furthermore the ET-1 were not correlated with the clinical score and renal
involvement was independent from the ET-1 measurements. However, the urinary ET-1 levels
were a significant predictor of the duration of the acute phase of HSP (HR = 0.98, p = 0.032,
CI0.96–0.99). The ET-1 levels did not correlate with the duration of renal involvement.
Conclusion: Urinary ET-1 levels are a useful marker for the duration of the acute phase of HSP
but not for the length of renal involvement.
Background
Henoch Schonlein purpura (HSP) is a well known sys-
temic small vessel vasculitis characterized by major mani-
festations; arthritis, nonthrombocytopenic purpura,
abdominal pain and renal disease. The latter is of major
concern since it may result in lifelong problems. Although
the pathogenesis of HSP remains largely unknown there is
strong evidence that IgA has a pivotal role given the
increased serum IgA concentrations, IgA with concomi-
tant circulating immune complexes and IgA deposition in
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vessel walls and renal mesangium have been observed
during the course of the disease. Furthermore, activation
of the alternative pathway of complement and cytokine
abnormalities has also been implicated as having a role in
HSP pathogenesis [1].
Endothelins (ETs) were first found by Yanagisawa et al. in
1988 [2] and 3 isoforms of this peptide, ET-1, ET-2, ET-3,
have been isolated [3]. Their biological activities cover a
wide spectrum which includes regulation of hormones
and neurotransmitter, cellular growth and proliferation,
bronchoconstriction, natriuresis and water diuresis (4).
Urine contains higher concentrations of ET compared to
those of plasma which is mainly derived from the in situ
production by the kidneys [4].
Endothelin-1 (ET-1) is a potent vasoconstrictor and its
concentrations in plasma are increased markedly in a
number of pathologies, such as ischemia induced damage
and reperfusion, vasculities of various types, congestive
heart failure, systemic inflammatory response seen in sep-
tic shock syndrome and similar pathology [5]. In a study
by Muslu A et al. it was shown that ET-1 plasma levels
were significantly higher in HSP patients during the acute
phase compared to levels in remission but also to levels in
healthy controls [6].
The purpose of this study was to determine whether ET-1
levels in plasma and urine are related to the severity of the
clinical presentation and the outcome of HSP.
Methods
Thirty patients with HSP were recruited during a 2 year
period from January 2005 to December 2006. The control
group consisted of an equal number of healthy children
matched for age and gender. The age range was 2–12.6
years with a mean of 6.3 ± 3 years. The respective ages for
the controls were 2–12.7 years and 6.2 ± 2.6 years. Male
to female ratio was 14/16 in both groups. Informed con-
sent was obtained from the parents of all participants and
the study was approved by the Local Ethics Committee.
The diagnosis of HSP was based on the criteria established
by the American College of Rheumatology [7]. A punch
skin biopsy was performed in all patients in order to verify
the diagnosis. Biopsies were obtained from affected and
non affected skin within 48 hours of the appearance of the
lesions.
A detailed history and a complete physical examination
were obtained from all patients. A clinical scoring system
adjusted from De Matia D et al. and Muslu A et al. which
consisted of the sum of three distinct scores for arthritis,
abdominal symptoms and renal involvement were used
to assess disease activity and severity [6,8]. This score was
modified by using more objective criteria (Table 1). Sever-
ity of the disease was determined as mild or severe, if the
clinical score was ≤ 4 or > 4, respectively
Laboratory measurements included complete blood
count, erythrocyte sedimentation rate (ESR), C reactive
protein (CRP), total protein and albumin, blood and
urine electrolytes, immunoglobulins (IgA, IgG, IgM), C3,
C4, ASO, ANA, anti-DNA, Ra test, p-ANCA, blood urea
nitrogen (BUN), creatinine, culture of pharyngeal swab-
bing and stool guiac test and routine urinalysis (which
was performed every 15 days during the study period). In
a random urine specimen taken at the same time with the
creatinine blood sample, ET-1(expressed as creatinine
ratio) and N-acetyl-b-D glucosaminidase (NAG-
expressed as creatinine ratio), was measured as a sensitive
Table 1: The clinical scoring system in patients with HSP (6, 8)
Arthritis score
0 = No symptom
1 = arthralgia and/or slight swelling (normal walk)
2 = arthralgia and/or moderate swelling (limp walk)
3 = arthralgia and/or severe swelling (refuse to walk)
Abdominal score
0 = No symptom
1 = mild abdominal pain(medically elicited) and/or occult blood in stool (+)
2 = moderate abdominal pain (transient complaints brought to medical attention) and/or occult blood in stool (++/+++)
3 = severe abdominal pain and/or melena and/or hematemesis and/or intussusception
Renal score
0 = No proteinuria and/or 3–5 RBC/HPF
1 = proteinuria 30 mg/dl and/or microalbuminuria and/or 10–15 RBC/HPF)
2 = proteinuria 30–150 mg/dl and/or > 50RBC/HPF
3 = proteinuria 150 mg/dl and/or macroscopic haematuria
RBC: red blood cellsBMC Pediatrics 2008, 8:33 http://www.biomedcentral.com/1471-2431/8/33
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marker of tubular damage. Creatinine, total protein and
a1 and b2 microglobulin were also calculated in a 24
hours urine collection as tubular markers and microalbu-
min as a marker of glomerular damage. The children who
presented with gross or mild haematuria and/or proteinu-
ria and/or tubular or glomelural involvement were con-
sidered as having renal involvement.
Venous blood samples for plasma ET-1 determination
were collected in frozen plastic tubes containing EDTA
(0.1 ml EDTA/ml of blood) after 30 min of supine rest.
They were promptly centrifuged and stored in tubes con-
taining aprotinine at -70°C until analyzed. Plasma ET-1
levels were determined by radioimmunoassay (RIA)
(Endothelin 1–21 specific [125I] columns (Amersham Bio-
sciences Amprep™ 500 mg C2 columns). The sensitivity of
the assay was 1.2 pg/ml. The intra and inter assay variabil-
ity were 4.8% and 13.8% respectively. Urinary NAG levels
were measured following a fluorometric method
described by Leadback and Walker [9] as well as by Woo-
len and Walker [10] and subsequently modified by Gnan-
adurai et al [11]. The urinary creatinine levels were
analyzed by Jaffe's method for calculating NAG/creatinine
quotients [12].
Patients were examined and underwent all the aforemen-
tioned laboratory tests at 3 distinct time points. The first
at the time of diagnosis of HSP corresponding to the acute
phase. The second, 1 month later or when renal involve-
ment was diagnosed (which ever happened first) and the
third 1 year later which roughly corresponded to the
remission of the disease. Four patients continued to
present with renal impairment even after 15, 24, 14 and
18 months respectively and for that reason their last
examination did not correspond to their remission phase.
Statistical methods
Continuous variables are expressed as mean ± SD whereas
time variables as median (p50), 25th percentile (p25) and
75th percentile (p75). In univariate analysis we compared
means between different groups with t-test and one way
Anova and we used Spearman's rho to search for any cor-
relations between variables. In multivariate analysis, we
used logistic regression to see if ET-1 was a predictive fac-
tor for renal damage and Cox Proportional Hazard mod-
els which were used to estimate relative risk [expressed as
hazard Ratio (HR)] of remission associated with a unit
change in a covariate, to explore for any correlations
between ET-1 and the length of the disease. We used the
backward procedure for selecting the best models. The sta-
tistical significance threshold was set at p < 0.05.
Results
Twenty-three (76.6%) of our patients had mild and 7
(23.4%) had severe disease. Rash was evident in all
patients at presentation. In 12 (40%) of them it was pre-
ceded by: arthritis, in 6 (20%) by gastrointestinal com-
plaints, in 5 (17%) hematuria in 1 (3%). Histological
examination of the skin biopsies revealed typical leuko-
cytoclastic vasculitis in all patients; whereas immunofluo-
rescence studies showed perivascular IgA deposition in 28
(93.3%), C3 deposition in 13(43.3%) and IgM deposi-
tion in 5 (16.6%) patients.
During the course of the disease, arthritis occurred in 25
(83%), gastrointestinal involvement in 24 (80%) and
renal involvement in 18 (60%) patients. Blood pressure
was within normal limits in all patients apart from 1 who
developed nephritic syndrome.
Only one patient who finally developed nephrotic syn-
drome, had low total protein and albumin. Four more
patients had proteinuria, which was not at nephrotic lev-
els and 10 microalbuminuria. Levels of NAG, a-1 and b-2
microglobulin were within normal limits in all patients.
The clinical hallmark of HSP nephritis is haematuria. In
our study 12/30 (40%) patients had microscopic and 5/
30 (16.6%) developed gross haematuria. Four patients of
the latter group finally developed proteinuria and two of
them underwent renal biopsy which revealed glomeru-
lonephritis characterized by diffuse hypercellularity and
mesangial proliferation.
Laboratory assays taken at presentation, were within nor-
mal limits with the exception of raised IgA in 14/30
(46%), elevated C3 values in 1/30 (3.3%) (Table 2), and
high ASO titers (> 200 IU/ml) in 17/30 (56%). The cul-
ture of pharyngeal swabbing was positive for group A beta
hemolytic streptococcus in 11/30 (36%).
Positive stool guiac test was detected in 16 (53.3%), hae-
matemesis in 2 (6.6%), melena in 4 (13.3%) and intus-
susception in 1 patient. The duration of time variables
expressed as median (P50) and 25th and 75th percentile
(p75, p25) in days were 8 (14,5) for the acute phase of the
disease, 45(362,5) for microhaematuria and 34(92,5) for
microalbuminuria.
No differences were found in ET-1 levels in plasma and
urine between patient and control groups at each of the
three distinct time points (Table 3). Also there was no cor-
relation between renal or overall clinical score and ET-1
values in plasma and urine on the 3 time points (Table 4,
5) between patients with and without renal involvement
(Table 6).
Of note, in order to investigate if any correlation existed
between ET-1 in acute phase and renal involvement, we
used two logistic regression models (one for ET-1 in
plasma and one for ET-1 in urine) and in each one weB
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Table 2: Clinical score and selected laboratory values in patients with HSP, at presentation (IgA, C3) and at three distinct time points (ET-1).
1st time point 2nd time point 3rd time point
Patient No Age (years) 
/Gender
(M/F)
IgA 
(mg/dl)
C3 
(mg/dl)
Clinical 
score
ET-1 
in plasma
(pg/ml)
ET-1 
in urine 
(pg/ml)
ET-1 
in plasma 
(pg/ml)
ET-1 
in urine 
(pg/ml)
ET-1  
in plasma
(pg/ml)
ET-1  
in urine
(pg/ml)
1 5./F 261 204 2 15.388 9.147 16.2 40.112 16.57 39.742
2 9.5/F 162 141 1 17.568 22.843 16.75 60.149 16.78 56.631
3 10/F 802 139 2 9.96 75.957 21.55 24.874 15.64 39.401
4 2/M 101 116 3 13.519 55.413 16.64 25.85 15.89 38.46
5 2/M 107 118 1 9.158 53.148 14.56 23.69 15.6 37.75
6 11.5/M 278 128 3 15.637 23.54 16.63 30.71 16.97 25.589
7 10.5/F 254 141 3 8.099 21.07 14.26 85.07 15.97 61.322
8 4/F 171 108 4 14.329 34.932 17.5 27.258 15.72 45.46
9 5.5/M 323 121 6 18.316 43.31 16.69 52.272 16.47 48.37
10 5.5/M 261 116 7 15.45 40.02 11.4 30.616 11.08 11.505
11 12.5/M 223 172 5 8.659 12.346 10.65 20.706 19.17 113.235
12 2/F 81.7 147 2 14.515 35.614 15.26 42.23 15.97 38.46
13 11/M 218 148 1 16.69 31.3 14.39 22.357 15.9 34.093
14 3.5/F 112 127 1 16.63 34.646 19.62 42.578 23.5 41.68
15 3.5/F 210 104 1 12.46 16.329 17.75 73.666 16.26 45.03
16 8/F 288 137 2 14.57 48.38 17.38 45.133 16.34 44.627
17 8/M 204 151 2 15.64 23.78 17.88 28.657 15.98 36.95
18 8/F 402 116 3 26.53 32.51 18.25 86.823 17.62 89.72
19 5..5/F 133 152 3 17.13 25.918 14.82 30.406 14.98 42.78
20 2/M 129 119 5 13.7 22.774 17.88 52.463 23.45 30.821
21 7/F 239 164 4 16.19 43.74 17.38 38.13 7.78 97.409
22 8.5/M 143 143 2 16.57 20.225 16.01 37.31 15.79 44.63
23 7.5/M 156 106 8 11.21 23.737 18 63.22 23.31 95.465
24 4/F 193 141 3 18.87 16.731 8.72 23.641 15.34 38.538
25 4/M 377 117 4 18.87 33.195 22.75 58.51 19.41 44.75
26 5/M 179 147 3 18.06 48.372 13.39 28.513 8.16 28.113
27 7.5/F 174 139 3 26.8 20.227 21.5 59.855 15.5 19.893
28 6.5/M 284 147 5 19.49 31.143 11.21 51.412 10.77 31.48
29 4/F 114 96 1 12.27 181.192 16.82 25.594 17.55 37.985
30 3.5/F 197 130 7 17.56 41.909 11.58 28.575 14.84 48.859
Normal values of IgA (mg/dl)
4–6 months 4.4–84
7–12 months 11–106
1–5 years 14–159
6–10 years 33–236
Adults 70–312
Normal values of C3 (mg/dl)
1–3 months 53–31
3–12 months 62–180
1–10 years 77–195
Adult 83–177BMC Pediatrics 2008, 8:33 http://www.biomedcentral.com/1471-2431/8/33
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adjusted for potential confounders namely, age, gender
and clinical and laboratory parameters that were meas-
ured during the acute phase of the disease i.e. clinical
score, ESR, CRP, IgA and C3. Our results show that renal
involvement and ET-1 were not correlated (OR = 1.05,
95% CI 0.79–1.383, p = 0.74 and OR = 0.99 95% CI 0.95–
1.03, p = 0.71 for ET-1 in plasma and urine respectively).
Using Cox Proportional Hazards models and controlling
for the same potential confounders as above, we tried to
investigate whether ET-1 was correlated with the length of
the acute phase of the disease. We found that there was no
significant correlation with ET-1 in plasma but ET-1 in
urine was a significant predictor for the length of the acute
phase (HR = 1.01, p = 0.79, 95% CI 0.91–1.11 and HR =
0.98, p = 0.032, 95% CI 0.96–0.99 for ET-1 in plasma and
urine respectively). The latter result implies that the
higher the levels of ET-1 in urine, the longer the acute
phase. A more precise expression of the latter result is that
for one unit increase in ET-1 in urine, the mean rate of
remission of acute phase (instantaneous remission rate) is
reduced about 2%.
We also investigated the relation between ET-1 levels dur-
ing the acute phase and the length of microhaematuria
and microalbuminuria adjusting for the same potential
confounders as before. We found that ET-1 in plasma and
urine did not correlate with renal involvement although
ET-1 in plasma showed a trend toward a significant corre-
lation with the duration of microhaematuria (H.R. = 1.51,
p = 0.055, 95% CI 0.99–2.34).
Discussion
HSP is the most common vasculitis in childhood. It is a
multisystem disease most commonly affecting skin,
joints, gastrointestinal tract and kidneys although other
organs may also be affected [13]. Its pathogenesis remains
largely unknown. However, it is generally considered to
be an immune complex-mediated disease characterized
by the presence of polymeric IgA1 containing immune
complexes which are mainly found in dermal, gastrointes-
tinal and glomerular capillaries [14]. IgA aggregates or IgA
complexes with complement deposits in target organs,
result in elaboration of inflammatory mediators, includ-
ing vascular prostaglandins such as prostacyclins which
are thought to play a role in the pathogenesis of HSP vas-
culitis [15].
Alterations in the production of interleukins and growth
factors may also have a role in the pathogenesis of HSP.
Tumor necrosis factor (TNF), interleukin 1(IL-1) and
interleukin-6 (IL-6) may mediate the inflammatory proc-
ess present in HSP [1,16,17]. There is only one study
which demonstrated that plasma ET-1 levels in the acute
phase were significantly higher compared to the remission
phase and to the controls. However plasma ET-1 levels did
not correlate with the clinical and laboratory findings
with the exception of a minority of patients with severe
disease [6]. In our study we did not find any differences of
plasma and urine ET-1 levels between patients and con-
trols.
Table 3: ET-1 plasma and urine levels at 3 selected time points in HSP patients and controls
ET-1 in patients (mean ± SD)) ET-1 in controls (mean ± SD) p
1st measurement Plasma 15.66 ± 4.30 16.75 ± 5.96 0.41
Urine 37.44 ± 30.78 45.31 ± 20.33 0.24
2nd measurement Plasma 16.11 ± 3.26 16.75 ± 5.96 0.60
Urine 42.01 ± 18.64 45.31 ± 20.33 0.51
3rd measurement Plasma 16.14 ± 3.60 16.75 ± 5.96 0.63
Urine 46.95 ± 23.15 45.31 ± 20.33 0.77
Table 4: ET-1 values in plasma and urine at three distinct measurements in relation to renal score
ET-1 (mean ± SD, range) Renal score (Mean ± SD, range) rho p
1st measurement Plasma 16.20 ± 5.18, 2.18–26.80 0.70 ± 0.91, 0–3 -0.011 0.95
Urine 41.38 ± 26.17, 9.14–181.19 0.099 0.59
2nd measurement Plasma 16.11 ± 3.26, 8.72–22.75 0.73 ± 1.08, 0–3 -0.180 0.92
Urine 42.01 ± 18.64, 20.70–86.82 0.248 0.57
3rd measurement Plasma 16.14 ± 3.60, 7.78–23.5 0.1 ± 0.30, 0–1 -0.288 0.52
Urine 46.95 ± 23.15, 11.50–113.23 0.473 0.66
Results from univariate analysis (rho = spearman's correlation coefficient)BMC Pediatrics 2008, 8:33 http://www.biomedcentral.com/1471-2431/8/33
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ET was initially described as a peptide released from large
vessel endothelial cells [2]. However other sites of synthe-
sis have subsequently been discovered. ET is also
expressed in brain, lung, heart and kidney. As far as the
latter location is concerned endothelial, glomerular, tubu-
lar epithelial and mesangial cells of the kidney can all syn-
thesize ET [18].
The circulating half life of ET is short (2–3 min) and it is
almost completely metabolized in the pulmonary capil-
laries by the enzyme neutral endopeptidase. A small
amount of circulating ET is cleared in the urine [19].
Depending on the nature and the magnitude of the stim-
ulus circulating ET may be elevated in different patho-
physiological or experimental conditions. However it is
not clear whether an elevated level of circulating ET is nec-
essary for its actions [20]. The effects of ET are detected
long after the normalization of the plasma level. These
data suggest that the concentration of plasma ET does not
correlate with its activity in different cells and tissues and
the circulating levels depend on the balance of the lumi-
nal endothelial synthesis and metabolism [4].
The kidney and particularly the renal medulla expresses
the highest concentration of ET-1 receptors of any organ
and also synthesizes ET-1 [21]. Glomerular epithelial and
mesangial cells, renal tubular cells and medullary collect-
ing duct cells synthesize and release ET-1. ET-1 is a major
mediator of renal vascular tone, tubular secretion of elec-
trolytes and water and vascular smooth muscle and
mesangial cell proliferation [22]. ET-1 maintains normal
kidney perfusion by increasing renal blood flow, effecting
on natriuresis and diuresis [23].
Despite the higher concentration of ET in urine compared
to plasma, the urinary excretion of ET does not correlate
with the glomerular filtration rate filtered load or plasma
levels [24]. It has been suggested that the filtered ET is sub-
ject to proteolytic degradation by neutral endopeptidase
across the brush border of the proximal tubuli [19]. ET
can be a marker of renal injury in different pathological
processes in children and in adults but its specificity is
low. Therefore ET should be used with caution as a marker
of distal tubular or collecting duct epithelial function [4].
ET/creatinine ratio in random urine samples could be
used as a reliable index of urinary excretion of ET [25,26].
In our study this urinary ET-1 was correlated with the
duration of the acute phase of the disease.
Several systemic rheumatic diseases in which vascular
pathology is related to endothelial cell activation appear
to be causally related to endothelin.
They include systemic sclerosis, systemic lupus erythema-
tosus, Takayasu and giant cell arteritis, Raynaud's phe-
nomenon, mixed cryoglobulinaemia, aortoarteritis and
Buerger's, Bechcet, Kawasaki, mixed connective tissue and
Chaga's disease [27-38]. All these studies measured only
plasma ET-1 levels in contrast to our study which meas-
ured plasma and urine ET-1 levels (although no differ-
ences between patients and controls were found).
Table 5: ET-1 values in plasma and urine at three distinct time point measurements in relation to clinical score.
ET-1 (mean ± SD, range) Clinical score (mean ± SD, range) rho p
1st measurement Plasma 16.20 ± 5.18, 2.18–26.80 3.23 ± 1.94, 1–8 0.145 0.443
Urine 41.38 ± 26.17, 9.14–181.19 -0.032 0.864
2nd measurement Plasma 16.11 ± 3.26, 8.72–22.75 0.73 ± 1.08, 0–3 -0.018 0.923
Urine 42.01 ± 18.64, 20.70–86.82 -0.106 0.576
3rd measurement Plasma 16.14 ± 3.60, 7.78–23.5 0.13 ± 0.34, 0–1 0.011 0.952
Urine 46.95 ± 23.15, 11.50–113.23 0.237 0.205
Results from univariate analysis (rho = spearman's correlation coefficient).
Table 6: ET-1 values in plasma and urine between patients with and without renal involvement (RI).
Patients with RI Patients without RI p
1st measurement Plasma 15.77 ± 4.48, 8.6–26.8 15.56 ± 4.29, 8.09–26.53 0.851
Urine 35.59 ± 16.80, 12.34–75.95 39.06 ± 39.77, 9.147–181.19 0.506
2nd measurement Plasma 16.11 ± 3.26, 8.72–22.75 16.20 ± 3.25, 8.72–22.75 0.891
Urine 38.40 ± 14.64, 20.70–63.22 44.41 ± 20.94, 23.64–86.823 0.582
3rd measurement Plasma 16.86 ± 4.61, 11.08–23.31 16.00 ± 3.47, 7.78–23.5 0.977
Urine 60.63 ± 42.53, 11.50–113.23 44.22 ± 17.30, 19.89–97.40 0.486BMC Pediatrics 2008, 8:33 http://www.biomedcentral.com/1471-2431/8/33
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Conclusion
In conclusion, plasma ET-1 levels cannot be utilized as a
predictor of HSP duration or severity whereas urine ET-1
levels are correlated with the duration of the acute phase
of the disease.
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